Business model design and business model innovation examine the various options of how to make a new or existing business (more) valuable and viable. For this assignment we distinguish Business Model Creation and Business Model Innovation.
The starting point for Business Model Creation is usually a business idea, an invention, technological advancement, and the discovery of a market niche or any other knowledge that may promise successful commercialization. Creating a new business model means experimenting with the combination of various factors that jointly do not yet exist in a given market context and together present a unique way of gaining competitive advantage.
The starting point for Business Model Innovation is usually an existing business that for some reason has become or is in danger of becoming less viable. This could be the case because competing products and services have taken away market share or due to increased global competition, changing access to key resources etc. that lead to lower margins. The reasons for why an existing business model weakens are numerous. In any case, such situation means that strategists are asked to re-position the business or re-think how value can best be created and delivered.
The strategic management and innovation methods, tools and techniques being used for either situation are largely the same. This assignment requires you to individually create a new business model. Having gained a sound understanding of the various elements of a Business Model you will now chose a market context and start exploring the options for improved or new business models.
The four key tools and techniques used in this assignment are the Business Model Canvas (BMC), the Value Proposition Canvas (VPC), the Blue Ocean strategy and Test Cards as well as some other related Strategic Management techniques.
You are going to engage directly with existing and potential customers, talk to existing and potential suppliers, or other stakeholders for the purpose of gathering important information, evidence and support for the creation of value propositions and related business model options.
Your task is to imagine, explore, test, verify and articulate the elements of a BMC and VPC and to ensure their fit. You might apply a business model pattern or a combination of patterns. Importantly, blue ocean strategy and tool should be employed to justify the viability of your idea. Additionally, test cards should be employed to prove that the idea is workable
How to Start:
Start by choosing a market or industry context in which you like to create or innovate a business model.
do the following::
• Take an idea for a business that you already have and create a business model for it. I would like to export solar panels to a developing country
PAS was first presented as first line medicate yet being supplanted by Ethambutol in 1960s1. It acts bacteriostatically with having inhibitory impact at focus under 1mg/ml by meddle with folic corrosive digestion in bacteria1. PAS is promptly assimilated from gastrointestinal tract and disseminated well all through the body. Around 80% of the medications will be discharged by means of kidney in the wake of being processed to acetylated form1. Moxifloxacin and Gatifloxacin are both been combined and assessed as astounding bactericidal specialists through restraining DNA gyrase, an ATP-subordinate catalysts topoisomerase II which is capable in microscopic organisms DNA transcription9. DNA gyrase is comprised of two subunits that is organized in a complex, is encoded by two distinct qualities, gyrA and gyrB where transformations at gyrA will regularly make microbes protection these new age of flouroquinolones9. Because of the expanding occurrence of multidrug protection TB, it is profoundly attractive to grow new medications that are not just powerful and viable against current safe strains of M. tuberculosis yet additionally have shorter treatment term since the vast majority of the incompliance of patients is raised by protracted TB treatment. A large portion of the components of activity of current medicines are engaged with meddling the bacterial DNA amalgamation, protein and mycolic cell divider biosynthesis. The proteins that take an interest in these pathways could likewise be the objective of recently outlined medications, for example, TMC207, one of the new medications which are right now under examinations and clinical trials. TMC207 is an individual from diarylquinoline class of compound which focus at adenosine triphosphate (ATP) synthase by authoritative to subunit C of the synthase, obstructing the vitality pathway of mycobacteria22, 23. In vitro, TMC207 not just has capacity to repress both medication delicate and safe M. tuberculosis confines, yet in addition ready to clean the patient through slaughtering the lethargic bacilli bactericidally22. TMC207 demonstrated a base inhibitory centralization of 0.03ug/mL against M. tuberculosis, proposing a more intense specialist contrasted with current first-line medications, for example, isoniazid and rifampicin23. Aside from that, its synergistic impact with pyrazinamide could guarantee as compelling medication blend for sanitizing the patients against TB22. A stage I clinical trials which included short terms organization of TMC207 in solid people demonstrating no unfriendly impacts and the subjects are all around endured with it23. Be that as it may, it is basic to explore the selectivity of TMC207 against mammalian ATP synthase with longer periods to guarantee the patients’ wellbeing when controlled with TMC207. Thiacetazone (TAC) is generally utilized as second line hostile to TB specialist against multiresistant tuberculosis at present24. TAC acts by meddles the biosynthesis pathway of mycolic corrosive in tubercle bacilli24. The way that M. tuberculosis has been hard to annihilate and stays tenacious is because of its cell divider that made out of mycolic corrosive which is safe against concoction damage, parchedness and furthermore has low penetrability to antibiotics24. Mycolic corrosive contains cyclopropane rings that is actuated through cyclopropane mycolic corrosive synthase (CMASs), has a noteworthy commitment to tuberculosis24. By repressing the cyclopropanation, the cell divider biosynthesis will then be intruded, presenting the bactericidal effects24. The point of this examination is to combination and assesses the analogs of Thiacetazone which may be potential hostile to tuberculosis operators. The analogs will be tried against various strains of mycobacteria in lab. The objective activities of these analogs will likewise be distinguished in light of the structure of the analogs. The above simple is combined when a benzylaldehyde responds with an essential amine. This is a buildup procedure and an imine is created. The progressions at position R1 to R3 with various electron pulling back gatherings are first wanted to be assessed. In any case, the arrangement is restricted since the relating structures are either inaccessible or excessively costly that falling outside the financial plan. After modified on the past analogs that were found and their particular MIC esteems got from lab, the structures of new analogs that will be assessed are at last dealt with. The R1 to R3 positions would be supplanted by either a – chloro or a – methoxy with R8 position would either be an amine, a methyl or a benzene ring. A chloro is utilized at position R1 to R3 since it is electron pulling back, huge and lipophilic particle though the methoxy assemble is electron giving, little and very lipophilic. For R8 position, an amine is chosen since it is electron pulling back and little. A methyl is additionally chosen since it is very lipophilic, little and electron giving. Then again, benzene ring which is profoundly lipophilic, neither electron giving nor pulling back gathering may differently affect the simple orchestrated. References: Patrick Brennan, Douglas Young (2008). Tuberculosis. 88(2), 85-86, 137-138, 162-163. Wellbeing Protection Agency. http://www.hpa.org.uk/HPA/ National Health Services. http://www.nhs.uk/Pages/HomePage.aspx Zaida Araujoa, Jacobus Henri de Waard, Carlos Fernández de Larrea, Rafael Borges, Jacinto Convit (2008). The impact of Bacille Calmette-Guérin antibody on tuberculin reactivity in indigenous youngsters from groups with high commonness of tuberculosis. Immunization 26, 5575-5581. Hart and Sutherland (1977). BCG and vole bacillus immunizations in the aversion of tuberculosis in immaturity and early grown-up life. Br Med J2(6082), 293-295. Worldwide Alliance for TB Drug Development. http://www.tballiance.org/home/home.php 57th release of British National Formulary: Section on Tuberculosis drugs, 316-317. Blumberg, H. M. et al. (2003). American Thoracic Society/Centers for Disease and Prevention/Infectious Disease Society of American: treatment of TB. Am.J.Respir.CareMed.167, 603-662. Suhail Ahmad and Eiman Mokaddas (2009). Late advances in the determination and treatment of multidrug-safe tuberculosis. Respiratory Medicine 103(12), 1777-1790. Frieden TR, Sherman LF, Maw KL, et al. (1996). A multi-institutional episode of exceptionally tranquilize safe tuberculosis: the study of disease transmission and clinical results. JAMA 276, 1229-1235. Mukherjee JS, Rich ML, Socci AR, et al. (2004). Program and standards in treatment od multi-sedate safe tuberculosis. Lancet 363, 474-481. Zhang Y. et al. (2003). Isoniazid. Tuberculosis 2, 739-758. Hardmn, J.G., L.E. Limbird, P.B Molinoff, R.W. Ruddon, A.G. Goodman (2006). Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 9, 1164-1165. Zhang Y, Heym B, Allen B, Young D, Cole S (1992). The catalase-peroxidase quality and isoniazid protection by Mycobacterium Tuberculosis. Nature 358, 591-593. Richard A. Slayden, Richard E. Lee and Clifton E. Barry (2002). Atomic Microbiology 38(3), 514-525. Rup Lal, Sukanya Lal (2005). Late patterns in rifamycin inquire about. BioEssays 16(3), 211-216. Hardmn, J.G., L.E. Limbird, P.B Molinoff, A.G Gilman (2001). Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 10, 1278-1281. Raghunandan Yendapally and Richard E. Lee (2008). Outline, blend and assessment of novel ethambutol analogs. Bioorganic and Medical science Letters 18(5), 1607-1611. McEvoy, G.K. (2007). Admerican Hospital Formulary Service. Besthesda, 551. Selman A. Waksman (1953). Streptomycin: Background, Isolation, Properties and Utilization. Science, 118(3062), 259-266. Sampson AE, Barry CE (1999). Dynamic General Meeting American Society Microbiology. 99, 635. Andreas H.D., Alexander Pym, Martin Grobusch et al. (2009). The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis. 360(23), 2397-2405. Anna C. Haagsma, Rooda Abdillahi-Ibrahim, Marijke J. Wagner, Klaas Krab, Karen Vergauwen, Jerome Guillemont, Koen Andries, Holger Lill, Anil Koul, and Dirk Bald (2009). Selectivity of TMC207 towards mycobacterial ATP synthase contrasted and that towardsthe Eukaryotic homologue. Antimicrobial Agents and Chemotherapy, 53(3), 1290-1292. Anuradha Alahari, Xavier Trivelli, Yann Guérardel, Lynn G. Dover, Gurdyal S. Besra, James C. Sacchettini, Robert C. Reynolds, Geoffrey D. Coxon, Laurent Kremer (2007). Thiacetazone, an Antitubercular Drug that Inhibits Cyclopropanation of Cell Wall Mycolic Acids in mycobacteria. PloS ONE, 2(12): e1343. Mycolic acids are a mind boggling blend of fanned, long-chain unsaturated fats, speaking to key segments of the exceptionally hydrophobic mycobacterial cell divider. Pathogenic mycobacteria convey mycolic corrosive sub-types that contain cyclopropane rings. Twofold bonds at particular destinations on mycolic corrosive antecedents are adjusted by the activity of cyclopropane mycolic corrosive synthases (CMASs). The last have a place with a group of S-adenosyl-methionine-subordinate methyl transferases, of which a few have been all around contemplated in Mycobacterium tuberculosis, to be specific, MmaA1 through A4, PcaA and CmaA2. Cyclopropanated mycolic acids are enter factors taking part in cell envelope penetrability, have immunomodulation and industriousness of M. tuberculosis. While a few antitubercular operators repress mycolic corrosive blend, to date, the CMASs have not been appeared to be medicate targets. We have utilized different correlative ways to deal with demonstrate that the antitubercular sedate, thiacetazone (TAC), and its substance analogs, hinder mycolic corrosive cyclopropanation. Sensational changes in the substance and proportion of mycolic acids in the antibody strain Mycobacterium bovis BCG, and also in the related pathogenic species Mycobacterium marinum were seen after treatment with the medications. Mix of thin layer chromatography, mass spectrometry and Nuclear Magnetic Resonance (NMR) investigations of mycolic acids sanitized from tranquilize treated mycobacteria demonstrated a critical loss of cyclopropanation in both the ?- and oxygenated mycolate sub-types. Also, High-Resolut>